M1 Kliniken AG (M12)
XETRA Stock Exchange · Germany · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 19.38 |
|---|---|
| 52-week range | 13.62 – 21.70 |
| Return, 1 month / 3 months | −1.7% / +13.7% |
| Return, 1 year / 3 years | +44.4% / +155.8% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 45 |
| Volatility (1 year) | 41.2% |
| Worst drawdown (1 year) | -27.8% |
| Average daily value traded | 0.07M EUR |
| Dividend yield | 6.2% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
M1 Kliniken AG is a German healthcare company that runs private clinics specialising in aesthetic medicine and plastic surgery. Its centres offer treatments such as hair transplantation, wrinkle therapy and other cosmetic procedures, and it also sells beauty and skincare products. The company serves private patients at locations in Germany and abroad, and it is based in Berlin.
On this site M1 Kliniken AG appears as a stock on the XETRA Stock Exchange (Germany), code M12, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 4 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
M1 Kliniken AG (M12) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 19.38 on 23 October 2026.
Its price-based Market X-Ray is 65 out of 100 (a fair price profile), ranking 175 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 44.4% and over the last three months it rose 13.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 83 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 12.9% | ||
| From 52-week high | -9.0% | ||
| Momentum | 85 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 13.7% | ||
| 6-month return | 26.7% | ||
| 12-month return, skipping the last month | 46.9% | ||
| Stability (higher is calmer) | 48 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 41.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -27.8% | ||
| Liquidity | 39 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.07M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 50 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 6.2% | ||
| Years with dividends | 3 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −2.4% |
|---|---|
| 1 month | −1.7% |
| 3 months | +13.7% |
| 6 months | +26.7% |
| 1 year | +44.4% |
| 3 years | +155.8% |
| 5 years | +179.7% |
Signals
| 50-day / 200-day average | 19.73 / 17.16 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.63 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 9 Jul 2026 | EUR 1.2000 |
| 17 Jul 2025 | EUR 0.5000 |
| 18 Jul 2024 | EUR 0.5000 |
| 26 Aug 2019 | EUR 0.3000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.